Viatris' Blepharitis Ointment Fails Phase III: Full Disclosure on Clinical Setback & Its Future

Breaking News: Get the full, transparent details on why Viatris's investigational MR-139 (pimecrolimus 0.3%) ophthalmic ointment for blepharitis failed its Phase III trial. Discover how the therapy did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing.